Verlicchi, A.; Canale, M.; Chiadini, E.; Cravero, P.; Urbini, M.; Andrikou, K.; Pasini, L.; Flospergher, M.; Burgio, M.A.; Crinò, L.;
et al. The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer. Life 2023, 13, 1915.
https://doi.org/10.3390/life13091915
AMA Style
Verlicchi A, Canale M, Chiadini E, Cravero P, Urbini M, Andrikou K, Pasini L, Flospergher M, Burgio MA, Crinò L,
et al. The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer. Life. 2023; 13(9):1915.
https://doi.org/10.3390/life13091915
Chicago/Turabian Style
Verlicchi, Alberto, Matteo Canale, Elisa Chiadini, Paola Cravero, Milena Urbini, Kalliopi Andrikou, Luigi Pasini, Michele Flospergher, Marco Angelo Burgio, Lucio Crinò,
and et al. 2023. "The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer" Life 13, no. 9: 1915.
https://doi.org/10.3390/life13091915
APA Style
Verlicchi, A., Canale, M., Chiadini, E., Cravero, P., Urbini, M., Andrikou, K., Pasini, L., Flospergher, M., Burgio, M. A., Crinò, L., Ulivi, P., & Delmonte, A.
(2023). The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer. Life, 13(9), 1915.
https://doi.org/10.3390/life13091915
